Severe combined immunodeficiency syndrome (SCIDS) is a heterogeneous group of inherited disorders characterised by the failure of cellular and humoral immunity. Children present with recurrent or persistent infections and without treatment die within the first year of life from overwhelming infection.' The prognosis of children with SCIDS has been transformed by bone marrow transplantation and data from a European collaborative study of affected infants (in which Newcastle upon Tyne and London are the participating centres in the UK) have shown 97°/0 long term survival for recipients of HIA identical sibling marrow and 52% survival for recipients of HLA mismatched (haploidentical) marrow from a parent.2 The survival rate for infants transplanted after 6 months of age is only 45%/o, however, compared with 70°/ in younger children. Although facilities for bone marrow transplantation for the treatment of SCIDS are available within the UK, many affected children without a family history are older than 6 months of age at referral, or are terminally ill with overwhelming infection, making transplantation a risky procedure.
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group is shown in the group.bmj.com on July 7, 2017 -Published by http://adc.bmj.com/ Downloaded from lymphocyte subset analysis, which costs about £75. This is surely justified when compared with the enormous cost, both human and financial, of the unsuccessful treatment of an infant with SCIDS diagnosed (and so treated) too late. We have initiated a prospective study of the protocol to evaluate further the implications of its adoption. At present, survival after haploidentical bone marrow transplantation in Europe is poorer than that in some American centres, one of the chief differences being age at diagnosis,2 and results also vary between European centres. We hope that a greater awareness of the importance of absolute lymphocyte counts among paediatricians will lead to earlier diagnosis and therefore improved survival for infants with SCIDS born in the UK.
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